This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with chronic kidney disease.

 NICE has produced a COVID-19 rapid guideline on chronic kidney disease. It recommends changes to usual practice to maximise the safety of patients and protect staff from infection during the COVID-19 pandemic.


This guideline was updated in August 2021. There are new and updated recommendations on:

These supplement the existing recommendations on:

See visual summaries on the recommendations for identifying CKD in adults, phosphate binders and managing proteinuria.

View identifying CKD in adults visual summary  View phosphate binders visual summary  View managing proteinuria visual summary

Who is it for?

  • Healthcare professionals
  • Commissioners and providers
  • People with chronic kidney disease, their families and carers

Is this guideline up to date?

We propose to update the recommendation on oral antiplatelet therapy for reducing cardiovascular disease in people with chronic kidney disease. For more information, see the update decision.

We are reviewing the evidence on SGLT2 inhibitors for people with chronic kidney disease and type 2 diabetes. See the SGLT2 inhibitors update decision for more information, and the guideline in development page for progress on the update.

Guideline development process

How we develop NICE guidelines

This guideline updates and replaces NICE guidelines CG182 (published July 2014), NG8 (published June 2015), and CG157 (published March 2013).

Your responsibility

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. It is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. 

All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.

Local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties.

Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.

  • National Institute for Health and Care Excellence (NICE)